Thu, Dec 25, 2014, 4:08 AM EST - U.S. Markets closed for Christmas

Recent

% | $
Quotes you view appear here for quick access.

Arrowhead Research Corp. Message Board

  • dmorfey dmorfey Oct 2, 2013 10:40 AM Flag

    Selling Arrowhead at this level...

    is the same as selling Apple at $60. How prudent was that..?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • this ain't NO Apple (YET) Prudent to take your risk capital out and let the profits ride as my experience tells me. I've held on into Trial Reports with both Risk Capital and Profits and have lost more than won. I've learned that if we get a great report, YES the stock will shoot up and I'll profit more with my FREE STOCK Postion, BUT the time delays between this PH-1 report and just setting protocol for PH-2 with the FDA can take a YEAR! People are not patient and the stock will drop over time and then I RELOAD to run up as FDA PH-2 is getting started and again when close to reporting PH-2 data. (DO IT ALL OVER AGAIN and AGAIN and AGAIN!) The FDA is the one body you don't EVER want to guess their decisions on. They constantly pull the rug out from many GREAT products for some of the most tiny reasons. NEW drugs are hard to get approved, but when you hit one or two in your life, it can change your lifestyle for sure. Good Luck to everyone. I'm out with my Risk Capital at this time to live another day, but I'm in with my profits generated over the past many weeks as this stock has made great strides forward.

      Sentiment: Hold

      • 2 Replies to wyattkap
      • I've held on into Trial Reports with both Risk Capital and Profits and have lost more than won.

      • Per last CC, you see that they believe PH2a and PH2b can be done much faster.

        "We are on schedule for regulatory filing in Hong Kong in Q4 for single dose Phase 2A with ARC-520 in chronic HPV patients. This will be a dose escalation study and we believe that we may start at an effective dose level and therefore begin to generate meaningful data immediately.

        Our goal is to complete the Phase 2A study in the first half of 2014. As Bruce mentioned completion of long-term GLP toxicology studies and initiation of a multi dose Phase 2B study of ARC-520 are planned for the second half of 2014."

        When I hear people say things like "then I RELOAD"... on a potentially explosive stock like this, I always translate that to mean "Then I will buy back in, at a much higher pps.".

 
ARWR
6.35+0.07(+1.20%)Dec 24 1:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.